Introduction
The extracellular matrix (ECM) is the complex three-dimensional acellular environment that is present in all tissues and is essential for life. Controlled remodelling of the ECM is required for development, wound healing, and homeostasis; however, uncontrolled remodelling contributes to a variety of disease states [1] . The ECM is crucial for tissue repair, acting as a dynamic scaffold to protect and support healing wounds and as an instructive platform for reciprocal signalling with cells. Precisely regulated spatiotemporal biochemical and biomechanical cell-matrix interactions are key to the efficacy and quality of repair processes. Understanding matrix signaling events during wound healing provides insights for the rational design of matrix mimics to control the outcome of tissue repair.
All vertebrates have evolved mechanisms to replace or restore damaged tissue. The spectrum of wound healing outcomes ranges from complete regeneration in zebrafish and salamanders to scar formation in adult mammals. The mammalian wound healing response is classically characterized by three stages (i.e., inflammation, proliferation and remodelling) with each stage inextricably linked to the ECM [2] . Tissue repair commences immediately following tissue injury and, in postnatal mammals, most often culminates in the replacement of the damaged tissue with an acellular fibrotic matrix (i.e., scar tissue) but the cellular and molecular mechanisms that underpin tissue repair and its failure to heal are still poorly understood. Fibrosis, accounting for nearly 45% of deaths in the developed world, is a major impediment to functional tissue healing [3] . While scarring of minor skin wounds will have little or no functional effect on the organism, fibrosis in other Table 1 Role and consequence of dysregulation of key matrix proteins during tissue repair.
Matrix protein
Role during tissue repair
Consequences of dysregulation
Collagen type I
• Protects healing wound • Forms scar matrix • Mechano-signaling
• Deficiency results in impaired wound healing, defective fibroblast proliferation, slow wound closure • Accumulated in fibrosis Collagen type III
• Regulates early stages of repair and fibroblast phenotype
• Deletion leads to increased myofibroblast differentiation, accelerated wound closure, and increased scar formation Collagen type IV
• Basement membrane integrity • Regulates neo-vascularization and growth factor release • Accumulation associated with abnormal tissue repair tissues (e.g., heart, esophagus, spinal cord) contributes to the manifestation and progression of a myriad of diseases. The present review focuses on some of the common regulatory features of ECM during wound healing and tissue regeneration. An overview of the deposited and remodelled matrix components during mammalian wound healing is provided alongside a comparison to natural examples of scar-free healing and regeneration. Finally, we review pre-clinical and clinical matrix-based strategies that attempt to exploit the role of the ECM to facilitate functional tissue remodelling. The aim of this Review is to provide an understanding of the importance of native ECM in wound healing and tissue regeneration and then present strategies aiming to recapitulate the ECM (as tissue derived ECM) to improve mammalian wound healing.
Matrix deposition and dynamics in the wound healing cascade
In mammals, the ECM consists of over 300 proteins, many with key functions in wound healing. Faithful wound healing requires finely tuned ECM deposition and remodelling. Disruption of matrix remodelling events and excessive matrix deposition can lead to impaired wound healing (i.e., fibrosis) [1] . The deposition of key ECM proteins and matrixassociated proteins during the wound healing cascade is wellorchestrated, and key to successful wound healing (Table 1) . The matrix structure and composition is a key regulator of homeostasis and disease [4] . However, the matrix does not act in isolation but guides cell responses initiated largely by the binding of integrin receptors to ECM ligands [5] . Fibrin and fibronectin are released from vasculature immediately after capillary damage to prevent extensive blood loss. Platelets release chemotactic growth factors to re-establish the epithelium, while neutrophils and macrophages begin clearing excess matrix and cell debris. Fibroblasts activate to myofibroblasts and deposit collagen, glycosaminoglycans (GAGs) and fibronectin (i.e., granulation tissue). Myofibroblasts, originating in part from epithelial-to-mesenchymal transition of various cells, produce collagen I enriched scar tissue to provide strength and protection to the healing wound. Myofibroblasts contract along matrix fibers to support wound closure and subsequently undergo apoptosis. Epithelial cells and fibroblasts deposit a basement membrane to establish tissue integrity and cell polarity. Angiogenesis along the newly deposited basement membrane leads to the formation of blood vessels to restore circulation. Collagen fibrils are then arranged and cross-linked over a period of months, and excess collagen is cleared (Fig. 1 ).
Matrix mechanics -how stiffness and force regulate tissue healing
Mechano-chemical feedback mechanisms between cells and the matrix regulate the wound healing cascade. The dynamic composition and architecture of the matrix during tissue repair alter the viscoelasticity of the wound bed, and in turn growth factor activation, cell adhesion, migration, and differentiation. Further, cell-generated traction leads to mechanical unfolding of proteins that reveals neo-interaction sites as an additional regulatory feature of ECM-mediated wound healing.
Fibronectin and collagens are the first matrix proteins deposited after tissue injury. Fibronectin fibrils can be mechanically unfolded by cells to regulate protein structure/function. Cytoskeletal tension leads to the reversible extension of fibronectin, exposing FNIII motifs and altering integrin-binding affinities and cell signaling [6] . The elasticity of fibronectin fibers assists collagen assembly, as collagen I fibers preferentially co-localize with more-relaxed fibronectin fibrils [7] . Similarly, tenascin-C and tenascin-X, which differ only in number of FNIII domains, can be mechanically unfolded to generate functional diversity and the ability to sustain cell-ECM or ECM-ECM interactions over long extensions [8] .
Collagen morphology determines the physicochemical properties of the collagen matrix and affects collagen degradation, fibrogenesis, and integrin-mediated mechanocoupling. Cell motility and the ability of cells to translocate collagen fibers are modulated by collagen stiffness and porosity, which together can induce a change in mode of migration [9] . Collagen I, a major constituent of scar tissue, has a fractal microarchitecture that confers stiff matrix properties that alter cellular responses, such as inducing epithelial-to-mesenchymal transition (EMT) and mesenchymal transcription responses through integrin-mediated mechanosensing [10] . Accordingly, in fibrotic processes, collagen I among the collagenrich connective tissue deposited by fibroblasts and myofibroblasts triggers an increase in myofibroblasts that in turn deposit matrix and propagate tissue fibrosis [11] . The mechanical properties of collagen are also associated with TGFβ activation via myofibroblast's integrin-mediated growth factor activation [12] .
Proteolytic matrix remodelling
During tissue repair, spatiotemporal expression of enzymes leads to cleavage of matrix proteins that modulates matrix morphology (i.e., mechanical properties) and biochemical signaling by releasing or unravelling bioactive matrix fragments known as cryptic fragments or matricryptins. Among the matrix degrading enzymes important for tissue repair are MMPs, ADAMs (a disintegrin and metalloproteinase), ADAMTSs (a disintegrin and metalloproteinase with thrombospondinlike motifs), and urokinase-type plasminogen activator. Proteolysis guides cell migration by local matrix degradation and modulate cell signaling. Moreover, matrix-degrading enzymes release (and activate) growth factors from the ECM.
MMPs belong to the zinc proteinase superfamily and are expressed by cells during tissue injury and repair. MMP activity is regulated by the activation of pro-enzyme or inhibition through endogenous tissue inhibitors of metalloproteinases (TIMPs). Twenty-two different human isoforms of MMP with distinct substrates and tissue distribution have been identified. The MMPs involved in tissue repair processes cleave matrix proteins including collagens, gelatin, laminin, fibronectin, proteoglycans, tenascin, vitronectin, and osteopontin in local matrix remodelling events. MMPs process matrix proteins during tissue injury and repair and also act on cellular junction and adhesion proteins. MMPs have been shown to cleave E-cadherin, an adherens junction protein responsible for epithelial cell sheet formation, to regulate epithelial cell extrusion and cell migration events [13] . MMPs interact with integrins to modulate cell adhesion and migration [14] . MMPs also regulate vascular remodelling by liberating sequestered angiogenic factors and by generating cryptic anti-and pro-angiogenic molecules [15] . Given the key roles of MMPs in tissue repair, increased MMP expression has been correlated with impaired wound healing and fibrosis [16] . Elevated levels of certain MMPs have been suggested as diagnostic markers of disease-state and therefore MMP-inhibition represents a potential therapeutic strategy for improving tissue healing outcomes [17, 18] . However, pharmaceutical targeting of MMPs is problematic, as poor selectivity and off-target effects of exogenous MMP inhibitors has led to multiple failed clinical trials [19] , highlighting a need for unique approaches to MMP targeting.
ADAMs and ADAMTSs are members of the zinc proteinase family and are involved in tissue repair, vascular remodelling and activation of growth factors. ADAMs have been found to be important in skin and human lens epithelium wound healing [20] [21] [22] . ADAMTSs degrade proteoglycans [23] , process pro-collagen to collagen [24] , regulate blood coagulation, and facilitate vascularization [25] [26] [27] .
The urokinase plasminogen activator receptor (uPAR) is an important regulator of ECM degradation and cell-ECM interaction. uPAR regulates the activity of the plasminogen activation system. Plasminogen activation is an extracellular proteolytic cascade generating plasmin-a protease that cleaves matrix, mediates clearance of fibrin clots, and activates MMPs critical for matrix remodelling and angiogenesis [28] . The uPAR cell surface receptor is able to regulate both extracellular proteolysis and well as integrin activity and signaling via matrix protein vitronectin, and thus also contributes to cell-matrix homeostasis [29] .
Scar-free healing: unique matrix environments in the embryo and regenerating organisms
There is enormous heterogeneity in wound healing among diverse organisms with some perfectly able to regenerate injured tissues and organs and others replacing damaged tissue with pathological connective scar tissue. The ECM provides a pro-regenerative microenvironment in fetal tissue healing and in regenerating vertebrates that may provide therapeutic opportunities for improving wound healing in humans (Table 2 ). In stark contrast to adult wounds, embryonic skin wounds heal rapidly and scar-free [30] . The neonatal heart also undergoes faithful regeneration [31] . In general, regenerative potential decreases with gestation time and continues to decline through lifespan, and it's clear that both cell-intrinsic (regenerative capacity) and cellextrinsic (regenerative environment) factors play a role in this decline [32] . The adult mammal regenerative potential is limited to cell turnover of epidermal, epithelial, and hematopoietic tissues. Fetal wounds differ from adult wounds in inflammatory response [33] and in ECM composition/dynamics, highlighting the role of matrix composition and architecture in scar-free healing [34] . The ratio of type I to type III collagen is higher in adult tissue repair processes compared to embryonic healing [35, 36] . Murine models of collagen III deficiency show increased scar formation, indicating an important role of collagen III in the regulation of scar tissue formation. Collagen I provides strength to the closing wound, but is the major constituent of the scar-forming matrix and a physical barrier to regeneration. Tenascin expression occurs earlier in the fetal wound compared to the adult [37] . Elevated levels of HA, a granulation tissue component and regulator of fibroblast phenotype and cell motility, is elevated in the fetal wound matrix which likely provides a more permissive matrix for cell movement and proliferation [38] . It has been further shown that there are differences in MMP and TIMP ratios between fetal and adult wounds, favoring matrix turnover and cell migration [39] . Changes in matrix composition, architecture and MMP expression further impact the release and activation of growth factors tethered to the matrix, such as TGFβ, to accelerate scar-free tissue healing in fetal tissue.
Insights into scar-free tissue healing can be gained by understanding how some non-mammalian vertebrates undergo tissue regeneration. Not surprisingly, dynamic breakdown and remodelling of the ECM is pivotal to tissue regeneration. Zebrafish, salamanders, and lizards are known for their regenerative capacity. Biphasic expression of MMPs is critical for faithful limb and tail regeneration in lizards and salamanders. The first wave of MMP expression is thought to promote epithelial cell migration while inhibiting basement membrane formation and the second phase of MMP expression is responsible for ECM remodelling and turnover [40] . The delayed basement membrane formation is an important distinction in regeneration vs. mammalian tissue repair. In most mammals, the basement membrane is restored during early stages of wound healing and is associated with a switch from collagen III to collagen I which is progressively cross-linked to an acellular fibrous scar. The benefit of rapid basement membrane formation is wound closure but this closure seems to act as a blockade for regeneration. In salamanders and fish however, expression of basement membrane constituents (e.g., collagen IV and laminins) is delayed until late stages of tissue healing/regeneration [41, 42] . Synthesis and cross-linking of collagen I is also delayed until final stages of scar free healing [42] . Increased expression of hyaluronic acid, tenascin, collagen III, fibronectin, and developmentally-associated collagens (e.g., collagen XII) may also be important to the regenerative ECM landscape [40] .
Strategies to reduce scarring
Fibrosis is the major contributor to the manifestation and progression of myriad diseases and represents one of the most compelling health issues in modern medicine. Scarring causes substantial morbidity; for example there is high incidence of fibrotic adhesions of internal organs in response to trauma, infection, radiation, or surgery that often leads to pain, bowel obstruction, and infertility. In diseases such as idiopathic pulmonary fibrosis, liver cirrhosis, cardiac fibrosis, systemic sclerosis and nephritis, fibrosis can lead to organ failure and death [2] . Despite the fact that fibrotic diseases account for nearly 45% of deaths in the developed world, there is currently no accepted therapy to target fibrosis [3] . However, insights gained over the past 2 decades into the molecular pathways driving fibrosis has informed the development of potential therapies. Despite unravelling key mechanisms and players in physiological and pathological tissue repair, there has not been substantial improvement in clinic in decades. Dozens of fibrosis therapies have been developed over the past decade and can be classified as pharmaceuticals, biomaterials, and cell therapies (Table 3 ). Strategies to target fibrotic disease is reviewed in detail elsewhere [43] [44] [45] and common therapeutic targets include TGFβ signaling, inflammation, and fibroblasts (i.e., homing, activation, and proliferation). Given that fibrosis is often characterized by several simultaneous profibrotic pathways, a multifaceted approach is likely key to success. The distinct challenge is in developing combination therapy approaches and identifying the delivery mechanisms and optimal delivery timing for each of the components. In the following section, we focus on matrix inspired approaches to limit fibrosis and achieve functional tissue healing.
Matrix-based materials for modulating tissue healing
The intimate role of the ECM in post-inflammatory tissue repair, wound healing, and fibrosis dispels the historic view of ECM as simply an inert support structure for cells. The ECM microenvironment in which cells reside is comprised of structural fibers, functional molecules, and a signaling repository which is highly heterogeneous and varies from tissue to tissue. ECM-cell interactions activate cellular responses (e.g., proliferation, differentiation, and migration) and tissue-specific cells are constantly secreting, assembling, and remodelling the ECM. Accordingly, the design and fabrication of ECM mimicking materials has been pursued for decades and represents a core strategy in tissue engineering.
Due to the complexity of composition, structural organisation, biomechanics, and dynamic roles of the ECM, synthesis of a high fidelity ECM mimic is not yet feasible. Numerous synthetic materials have been studied to provide multiplexed signaling to recapitulate some complexity of the regenerative tissue healing microenvironment [46] [47] [48] . One of the commonly used synthetics is polyethylene glycol (PEG) due to favorable chemical properties which has allowed integration of heparin, adhesion peptides, and growth factors into PEG-based hydrogels. Such PEG-based hybrid systems are responsive to exogenous Fig. 2 . Overview of matrix-based strategies to regulate tissue repair outcomes. The extracellular matrix (ECM) represents the non-cellular component of every tissue and organ. The matrix can be utilized in various ways based on application of interest. Appropriate tissue decellularization and sterilization processes can be used to prepare a mesh material suitable for filling/ bridging tissue defects. Acellular tissue can also be solubilized (e.g., with pepsin or acetic acid) to produce an ECM hydrogel that is suitable for injection or catheter delivery in minimally invasive procedures. Alternatively, specific bioactivity of defined components or cryptic fragments of ECM components can be exploited to mediate tissue repair processes. [60] ). (B) Zebrafish extracellular matrix induces mammalian heart regeneration. Extracellular matrix from normal (nzECM) and healing (hzECM) cardiac tissue was micronized and injected in an adult mouse acute myocardial infarct model. Compared to adult mouse cardiac ECM (mECM), the zebrafish ECM, especially the hzECM mitigated scarring as seen in Masson's trichrome stained sections (collagen in blue, cardiac muscle in red, scale bars = 1 mm, Adapted from [91] ). Heart sections labelled with CD68 showed a reduction in chronic inflammation at 6 weeks post-infarct when mice were treated with hzECM (CD68 in green, scale bars = 50 μm). (C) Extracellular matrix hydrogels implanted in a stroke cavity using a newly developed injection-drainage strategy promotes an acute endogenous repair response that could potentially be exploited to treat stroke. The hydrogel is infiltrated by host cells, typically of microglia, macrophage, or neural and oligodendrocyte progenitor phenotype, forms to the shape of the lesion, and the ECM components including GAGs (chondroitin sulfate and hyaluronic acid) and basement membrane proteins (laminin and collagen IV) can be detected over time (scale bars = 500 μm, Adapted from [101] ).
stimuli (e.g., light and enzymes) which can be used to dynamically introduce factors into the reparative process [49, 50] . Although considerable progress has been made in the development of synthetic biomaterials to partially recapitulate some of the elaborate functions of the ECM for tissue repair, ongoing challenges remain in controlling the temporospatial presentation of multiple signals. While the development of engineered synthetic materials represents a rapidly advancing field, the relative advantage that remains for naturally derived materials is inherent properties of biological recognition, with proper receptorbinding ligands and susceptibility to proteolytic degradation and remodelling. For this reason, this Review will focus on biologically derived ECM-like materials and provide context for ECM use in wound healing (Fig. 2) .
Components and cryptic fragments of the ECM
Individual ECM components have been isolated from tissues to study constituent effects on cell behaviour and to manufacture scaffolds for various applications. Matrix materials have been generated from purified collagens, fibronectin, fibrin, laminin, HA, and CS, among others. Purified type I collagen derived scaffolds are among the most common ECM-derived protein and are FDA allowed for several clinical applications, mostly as hemostatics and soft tissue fillers. Enzymatic cleavage of many ECM proteins can release or reveal bioactive fragments that exert biological activity which is distinct from the parent molecule. ECM proteins and their subdomains bind integrins and other cell surface receptors to regulate gene expression, cell differentiation, mitogenesis, and migration. Through the role of ECM fragments in directing cell activity and cell fate, matrix components regulate inflammation, angiogenesis, and scarring outcomes during wound healing. Given the interaction of the ECM with the wound healing process, there has been considerable interest in the cryptic fragments and degradation products of ECM for tuning wound healing.
Cryptic fragments have been described for a variety of matrix proteins and contribute to tissue healing events ranging from cell migration and epithelial-to-mesenchymal transition to the formation of blood vessels [51] . Selective ECM degradation generates microenvironments with unique biochemical and morphological ECM properties to instruct cell behaviour [52] . Past studies have shown relative success in use of matrikines as inhibitors of angiogenesis and inflammation, and angiogenesis inhibitors have been proposed in clinical studies for cancer therapy [53, 54] . Individual ECM fragments can also alter wound healing outcomes. A peptide fragment of lumican, a small leucine rich proteoglycan, has been shown to promote corneal wound healing following epithelial debridement, in part by mitigating TGFβ signaling [55] . Collagen IV contains hidden signaling molecules, such as arresten and canstatin that become active through proteolytic processing by MMPs and regulate angiogenesis after tissue injury by coordinating basement membrane remodelling and vascular sprouting [56] [57] [58] . Similarly, cryptic laminin fragments impact epithelial and endothelial cell migration and adhesion, angiogenesis, MMP activation, and EMT-related events involved in fibroblast differentiation and wound closure [59] [60] [61] . The laminin β1-chain-derived fragment, liberated by MMP processing, interacts with cells via α3β1-integrins and triggers down-regulation of active MMP2 in mouse and human ESCs [59] , and was recently shown in a pre-clinical study to prevent peritoneal fibrosis [60] (Fig. 3A) .
Individual fragments and cryptic sites of ECM provide interesting insights to the complex process of ECM remodelling during wound healing. Bioactive ECM fragments are potential drugs and have been tested in experimental models of cancer, wound healing, fibrosis and infectious diseases either as full-length fragments, modified fragments or peptides derived from their sequences, but their translation into the clinics is challenging. Clinical trials with recombinant collagen XVIII fragment (i.e., endostatin) as a cancer therapy have been largely unsuccessful in the US despite approved clinical use of endostatin in China [64] . However, there is still potential for endostatin as an anti-fibrotic [65] . Translation to date has been limited largely due to low potency of individual ECM fragments relative to the cognate ligands for the receptors known to trigger cell activation; for example, IL-8 binds and activates neutrophils at nanomolar concentrations [66] , while micromolar concentrations of chemotactic matrix-derived peptides are needed to activate neutrophils [67] .
Decellularized matrices
The concept of tissue decellularization is not new. The earliest reports of tissue decellularization date back nearly 7 decades, where in 1948 pulverization and freeze-thaw cycles were used to render muscle tissue acellular [68] . In 1991, an early tissue engineering study used allogeneic acellular dermal matrices as a biomaterial to facilitate reconstruction of skin with the use of autologous keratinocytes and fibroblasts [69] . The first use of xenogeneic tissue was described in 1989, where small intestinal submucosa (SIS) was used as a scaffold for vascular applications [70] . Since then, methods for preparing ECM scaffolds been developed and refined for nearly every tissue in the body [71] . All tissues are comprised predominantly of the same base biopolymers (i.e., collagens, glycans, laminin, elastin) with collagen I representing the majority of the matrix by weight. These unique properties of different decellularized tissues are therefore attributed to differences in biopolymer compositions and structures attributed to the cellular composition of the tissue. Numerous ECM scaffolds are now FDA-allowed and commercially available from a range of source tissues and species (Table 3) .
The objective of decellularization is to remove cell and antigenic components from a tissue while limiting damage to the underlying native ECM. The methods required to extract cells is a tissue-dependent procedure due to differences in cell density, matrix density, tissue thickness and shape among different tissues. Disruption of and removal of cells from tissues is typically achieved with physical treatments such as freeze-thawing, agitation, sonication, or mechanical pressure combined with detergents, ionic solutions, and/or enzymatic treatment which invariably causes some disruption of matrix. Methods of tissue decellularization have been reviewed in detail elsewhere [71] . Optimal decellularization processes require a balance between adequate cell removal and preservation of the matrix. Decellularization processes that are too harsh or too gentle can elicit adverse outcomes and proinflammatory responses arising from ineffective removal of antigens (e.g., α-gal or MHC-I epitopes), residual detergents, endotoxin contamination, or changes in the ECM structure [72, 73] . Complete removal of all cell organelles, lipid membranes, and cell-derived nucleic acids is likely not possible and there is measureable cellular debris in every ECM scaffold including those in clinical use [74, 75] , but given that such scaffolds are generally not associated with adverse reactions by patients it is suggested that levels of cellular debris below some threshold is acceptable. Despite potentially dire consequences of incomplete decellularization, quantitative metrics for decellularization still do not exist.
When prepared properly, ECM scaffolds can act as an inductive template for tissue healing. Numerous materials derived from decellularized tissues are used clinically to replace tissue in diverse applications including plastic and reconstructive, dental, orthopaedics, and cardiovascular procedures among others. The most extensive clinical use of ECM scaffolds is for hernia repair, where xenogeneic and allogeneic decellularized tissues like Surgisis®, Allomax®, and Alloderm®, are considered to have improved performance characteristics over synthetic mesh materials [76] [77] [78] [79] . Decellularized tissues have also aided in the healing of critically sized skin defects. Alloderm® has been shown to increase skin flexibility and improve scar quality in full-thickness wounds while Oasis® has facilitated complete healing in 60% of patients with chronic leg ulcers compared to 35% with the standard treatment [80] . Various decellularized dermis mesh materials are increasingly used in breast reconstructive procedures [81, 82] , and Alloderm® has also been used to facilitate frozen-banked ovarian tissue transplantation in the first reported pregnancies and live birth using this technique [83] . Decellularized tissues are commercially available in cardiac applications for the repair of heart valves (e.g., SynerGraft®) and pericardium (e.g., CorMatrix® ECM).
Along with the widespread use of ECM-based products, many preclinical and clinical studies continue to use decellularized matrices to improve healing of tissues including muscle, esophageal, and cardiac. In a clinical report of 13 patients from an ongoing trial (ClinicalTrials.gov Identifier: NCT01292876) with volumetric muscle loss, decellularized tissue was implanted and combined with aggressive physical therapy improved strength by 37% and range-of-motion tasks by 27% [84] . While more study is necessary, particularly to control for the effect of physical therapy and differences among 3 different ECM scaffolds used, this and another study suggest ECM can enhance the healing of volumetric muscle lesions to improve strength and function, albeit increased strength may not be attributable to appreciable de novo muscle formation [85] .
Decellularized tissues have also supported the reconstruction of tissues in the gastrointestinal tract [86] . In patients with superficial adenocarcinoma, restoration of the normal epithelial lining of the esophagus was achieved by implantation of a tubular ECM scaffold following en bloc circumferential resection of the diseased mucosa and submucosa [87] . A recent follow-up study showed this same strategy of mucosal resection with ECM scaffold placement also facilitates healing of tissue at the opposite end of the gastrointestinal tract in the colon/rectum [88] . The technique, informed by preclinical studies showing the ECM scaffold was necessary to support regrowth of mucosal tissue and prevent recalcitrant stricture [89, 90] is currently being studied in patients with esophageal high grade dysplasia (ClinicalTrials.gov Identifier: NCT02396745).
While an enhanced tissue healing response has been demonstrated with ECM materials, the ultimate goal to achieve scarless wound healing remains largely unmet. Studies in highly regenerative species like the salamander and zebrafish have highlighted the importance of the ECM in regenerative healing [40] . Building upon this concept, a recent study has shown that cardiac injection of particulate ECM derived from a healing zebrafish heart induced a regenerative effect in the murine heart following myocardial infarct. The authors showed proliferation of cardiomyocytes and cardiac precursor cells was induced by the injection of decellularized zebrafish cardiac tissue. The effect was associated with the higher level of neuregulin-1 in ECM derived from regenerating zebrafish myocardium compared to adult mouse cardiac ECM, and ErbB2 signaling was involved in inducing the regenerative outcome [91] (Fig. 3B) .
Despite many successes of decellularized tissues in preclinical and clinical settings, the field is still developing. It should be noted that outcomes associated with the use of ECM scaffolds have ranged from success to failure, and the reasons for this disparity are now mostly understood. Stated simply, not all commercially available decellularized tissues are created equal-differences exist among the source tissue, sizing, storage, proprietary processing, and sterilization. A recognized drawback on decellularized tissue matrices is the inherent heterogeneity among source tissues. For example, the composition of decellularized myocardial matrix from different cadaveric donors has measurable donor-to-donor variation [92] . Quantitative proteomics provides a tool that will likely improve the characterization and quality control of tissue derived scaffolds. A recent study described the use of proteomic methods to enable refinement of processing methods to attain high fidelity ECM constructs from lung tissue [93] . Still, heterogeneity between donor tissues can result in heterogeneity in decellularization. Implantation of the first decellularized porcine valve introduced in Europe, SynerGraft®, resulted in the death of 3 of 4 of the pediatric patients undergoing valve repair. Analysis of the SynerGraft® valves showed that decellularization was incomplete and resulted in severe inflammation and valve failure [94] . This outcome together with limitations due to tissue heterogeneity highlights the need for robust quality control measures for decellularized tissues.
Tissue-derived injectable hydrogels
The generation of tissue derived hydrogels from SIS in 1998 prompted the expansion in use of decellularized materials beyond the sheet or mesh materials described previously [95] . Tissue-derived hydrogels, or ECM hydrogels, represent a growing subset of injectable biomaterials in tissue engineering. Hydrogels are defined as highly hydrated polymeric materials with polymer chains and crosslinks to provide structural integrity. Natural ECM mimicking hydrogels contain natural polymers (e.g., collagen, aliginate, chitosan, or gelatin) and have been extensively studied and reviewed in detail elsewhere. Such hydrogels are composed of one or more purified ECM proteins and have promising applications. Single protein or collection of purified ECM components, although well-defined and relatively simple materials, is not able to recapitulate the complexity of the ECM microenvironment. Matrix-derived hydrogels with increasing complexity, although less defined, can be produced from decellularized tissues and have shown promise in mediating tissue healing outcomes.
Tissue derived hydrogels are formed through digestion of decellularized tissues. These gels are typically digested at low pH in a pepsin solution. Once the decellularized tissue is digested/in suspension, salt concentration and pH are balanced to physiologic levels and a gel forms spontaneously when warmed to 37°C. The soluble mixture is a viscous liquid below 22°C, and displays intermediate solid-like and fluid-like properties at 37°C [96] . Gel formation occurs through collagen self-assembly and is augmented by the presence glycosaminoglycans and other ECM proteins [97] . The source tissue from which the hydrogel is derived will impact the biochemical makeup and in turn the mechanical properties of the gel. Hydrogels have been formed and characterized from a range of decellularized tissues including adipose, gastrointestinal, heart, lung, and skin among others. A recent review nicely summarizes the structural and functional characteristics of such gels [98] . Tissue derived hydrogels have mechanical properties that are tunable by varying the concentration of matrix, providing some applicationspecific control of material properties. In some instances the hydrogels retain cues from the source tissue that can enhance cellular responses of tissue-specific progenitors. ECM hydrogels are cell-friendly and commonly used as a cell culture substrate. Several studies have shown improved or equivalent responses of cells grown on/in ECM hydrogels when compared to reconstituted basement membrane extract from Engelbreth-Holm-Swarm tumor (i.e., Matrigel®) or purified collagen. Promising results from in-vitro studies with ECM hydrogels have spurred increased study of such hydrogels in pre-clinical in-vivo studies. The delivery of solubilized ECM via catheter or syringe to irregularlyshaped anatomic sites provides increased utility of ECM-derived materials.
ECM hydrogels are injectable materials that allow for minimally invasive delivery to target tissues. The viscous soluble pre-gel ECM material is shear thinning, exhibiting a decrease in viscosity under shear, which enables injection of the ECM. Low viscosity of the pre-gel solution and gelation kinetics can be optimised to achieve minimally invasive injection with sufficient time required for delivery of the pre-gel solution to the anatomic site before gelation begins. The injectability through catheters or 18-27 gauge syringes has been demonstrated for ECM hydrogels derived from adipose, cartilage, dermis, intestine, liver, lung, muscle, and urinary bladder. The in-vivo application of ECM hydrogels has shown promise in a number of applications, particularly where there is an existing unmet need for minimally invasive therapies.
Tissue derived hydrogels have been tested pre-clinically as a therapeutic for skeletal muscle injury, defects in the central nervous system (CNS), myocardial infarction, and ulcerative colitis. In-situ polymerizing hydrogels composed of ECM enhance skeletal muscle remodelling in injury models. Hydrogels derived from both UBM and dermal ECM skeletal promote muscle remodelling in partial thickness abdominal wall defects with UBM treatment resulting in relatively higher myogenesis [99] . ECM hydrogel has also shown therapeutic benefits in treating skeletal muscle ischemia reperfusion injuries. In a rat hindlimb ischemia model, treatment with injectable ECM derived from skeletal muscle and umbilical cord increased tissue perfusion with an enhanced regenerative response elicited by skeletal muscle derived ECM hydrogel [100] . A number of studies have investigated the therapeutic potential of ECM hydrogels in treating tissue defects in the CNS. A recently described technique was used to deliver ECM hydrogels intracerebrally to a stroke cavity [101] , where UBM hydrogel at 8 mg/mL was shown to induce a cell infiltrate consisting of 60/30 mix of brain-derived/ peripheral macrophage phenotypes that may potentially be exploited for treating stroke lesions [102] (Fig. 3C) . ECM hydrogels have also been applied to traumatic injuries of the brain and spinal cord. Traumatic brain injuries treated with brain-derived ECM had reduced lesions volumes and improved neurobehavioural function, while UBM hydrogels reduced lesion size and improved motor function despite no measureable improvement in cognitive recovery [103] . Decellularized spinal cord and UBM hydrogels were used as a substrate to bridge lesions following spinal cord injury [104] . Catheter delivery of porcine myocardial matrix hydrogel has also been demonstrated as safe and effective in improving cardiac function following myocardial infarction in preclinical studies [105] and is currently the subject of clinical study (ClinicalTrials.gov Identifier: NCT02305602). A recent preclinical study in in rats with ulcerative colitis showed functional improvement in epithelial barrier function following treatment with SIS hydrogel [106] . The ECM was delivered as an enema and following in-situ gelation adhered to the colon wall more than 24 h, potentially expanding the applications for tissue derived hydrogels beyond treating only compartments or lesions of tissues.
Method of healing: modulating the inflammatory wound healing process
An inflammatory response is initiated following injury collectively by the presence of necrotic debris, the clotting reaction, and invading microbes and then is propagated by the local release of chemotactic factors. Innate immune cells (e.g., neutrophils, monocytes, and macrophages), which are recruited to the wound site to clear cell debris and microbes, orchestrate the tissue repair response. The degree and duration of the response varies, and this influences the final outcome [45] . Given that the implantation or injection ECM materials is inextricably linked to acute tissue injury at the site of application, it's not surprising that the success of ECM materials has largely been attributed to the ability of ECM to modulate the host response that commences upon implantation or injection. ECM materials are rapidly, within hours of implantation or injection, infiltrated by mononuclear cells. The ECM material then undergoes host-mediated biodegradation which is followed by an orchestrated spatiotemporal cellular response characterized by immune modulation and stem/progenitor cell mobilization, proliferation, and differentiation.
ECM degradation is a requirement for constructive tissue remodelling. The ECM material is infiltrated by host cells, especially macrophages, and the release of matrix metalloproteinases (MMPs) and other proteases contribute to the degradation of ECM. As a depot of biological signals, the degradable ECM materials act as vehicles for delivery of a variety of functional molecules. Decellularized tissues are rich in growth factors, bifunctional molecules such as fibronectin and various types of collagen, among other structural and functional molecules. Bioactive fragments of parent ECM molecules such as collagen, fibronectin, and laminin, are also generated by proteolytic degradation of the ECM [59, 60, [107] [108] [109] . The degradation rate of ECM scaffolds varies with the source tissue and the site of application. Besides a few studies with SIS ECM scaffolds, there is limited data on the degradation rate of ECM scaffolds. When used as a scaffold for Achilles tendon repair 60% of the SIS ECM mass was lost by one month after surgery, and the graft was completely resorbed by three months [110] . When placed in the urinary bladder, less than 10% of the original SIS ECM remained after 3 months [111] . In a model of abdominal wall repair, only 20% of the original the SIS-ECM remained after 4 weeks and the SIS ECM was resorbed by 6 months after implantation [112] . The degradation of ECM hydrogels is relatively fast compared to ECM scaffolds and, again, the rate of degradation/resorption is dependent on the application. For instance, ECM hydrogels injected into a tissue compartment degrade over weeks [105] , while enema preparations of ECM hydrogels delivered to the colon are cleared over days [106] . In summary, depending on the application, ECM degradation is necessary for constructive outcomes and ECM scaffolds are degraded over weeks to months while ECM hydrogels are degraded over days to weeks. ECM derived collagen molecules are stable in acidic solutions and are capable of subsequently forming fibrils that respond to body temperature and neutral pH to form physical cross-linking of the ECM hydrogel. The retention time of ECM scaffolds can be influenced by chemical (e.g., glutaraldehyde) or natural (e.g., Genepin) crosslinking as well, but whether it's beneficial or detrimental to tissue healing outcome is unclear [113] [114] [115] . Processing methods that affect the degradation of ECM materials, such as chemical crosslinking, will alter the release profile of degradation products and may impair tissue remodelling.
Immune modulation is a necessary feature of ECM mediated tissue remodelling. Despite being an underlying contributor to many degenerative and chronic diseases, inflammation plays an essential role in mitigating infection and mediating tissue healing. An intact immune system is necessary for faithful regeneration of the salamander limb [116] , zebrafish fin [117, 118] and zebrafish heart [119] . The regenerative capacity of mammalian tissues also relies upon an intact and tuned immune response [120] . While tissue healing and regeneration are initiated by inflammation, excessive or prolonged inflammation often promotes fibrosis. Macrophages, which have garnered the majority of attention in relation to tissue regeneration, act not only through their immune functions, but also control cell function and ECM remodelling. Macrophages are phenotypically diverse, and are key to both initiation/maintenance of inflammation as well as the inflammation resolution/regeneration processes. Research over the past 10 years with ECM-derived materials has correlated specific macrophage phenotypes with regenerative outcomes [121] . Decellularized tissues skew macrophages towards a predominantly M2 phenotype, which is regulatory and anti-inflammatory, and away from the pro-inflammatory M1 phenotype. This M2 majority seems to arise from a reduction in M1-like macrophages rather than an increase in M2-like macrophages. For example, ECM glycoproteins derived from various matrices diminished M1 function [122] , and delivering a porcine SIS gel to the colon in chemically-induced colitis abated the inflammatory response resulting in increased proportions of M2 macrophages [106] . Relatively less studied in the context of regeneration is the adaptive immune response but recent work has begun to elucidate the role of T cells in the immune microenvironment and, similar to macrophages, Th-2 cells have been shown to accelerate bone healing [123] and regeneration of injured muscle [124, 125] . There is still much to be learned about the mechanisms of matrix-based materials in generating a therapeutic immune response, but it's clear that a regulated scaffold immune microenvironment is a critical component of the regenerative niche [45, 126, 127] .
Conclusions
The essential role of the matrix influencing cell function and guiding wound healing provides a model for therapies to improve tissue healing outcomes. Scar-free healing in the embryo and regenerative organisms is guided by the ECM, and these examples provide opportunities for enhancing mammalian tissue reconstruction and regeneration. Stemming from increased biological understanding of the processes that dictate wound healing outcomes, biologically derived and synthetic materials equipped with molecular cues mimicking certain aspects of structure or function of natural extracellular microenvironments are quickly being developed. Design and use of synthetic biomaterials that can interact with environmental cues to actively participate in tissue healing represents an exciting frontier tin tissue engineering and has been reviewed in detail elsewhere [47] . Biologically derived scaffolds from decellularized tissue have been used clinically in reconstructive surgeries for decades. The success of these scaffolds in facilitating functional tissue healing is dependent largely upon a scaffold immune microenvironment and scaffold degradation, which has led to increased study of matrix degradation products. Components and novel cryptic fragments of ECM are revealed during matrix remodelling and elicit a wide range of signaling events and individual components have been used to tune wound healing outcomes and remains an interesting research direction. Hydrogels derived from decellularized tissues, which represents a complex mixture of ECM bioactive fragments, has emerged in recent years as a strategy to modulate the healing of various tissues. Although beyond the scope of this Review, the role of the extent and duration of inflammation influencing tissue repair outcomes cannot be overstated [45] . Positive tissue healing outcomes with matrix-derived components are most often associated with a modified inflammatory response but the mechanism by which this occurs is still poorly understood. Improved understanding of the dynamic matrix properties and matrix-inflammation interactions during regeneration, scar-free healing, and fibrotic outcomes will provide intervention checkpoints that may be exploited to guide clinical methodologies for improved tissue healing.
